Kiyatec is a private, commercial-stage company pioneering a functional precision oncology platform. Its validated, CLIA-certified laboratory service uses live patient tumor tissue to create 3D microtumors, testing them against various drugs to predict clinical response within 7-10 days. With a focus on solid tumors, the company is generating early revenue from its diagnostic service while expanding its clinical pipeline. Kiyatec's approach addresses a critical unmet need in oncology by aiming to replace empirical treatment selection with data-driven predictions.
Oncology
Technology Platform
Proprietary ex vivo 3D cell culture platform that creates patient-specific microtumors from live biopsy tissue to functionally test drug response.
Funding History
4
Total raised:$26.5M
Grant$2MNational Cancer Institute
Series B$15MLabCorp
Series A$8MLabCorp
Seed$1.5MUndisclosed
Opportunities
The primary opportunity lies in addressing the significant unmet need in oncology for functional, patient-specific drug response data to guide therapy selection, potentially improving outcomes and reducing ineffective treatment.
Expansion into high-incidence cancers like primary breast and lung, as well as difficult-to-treat brain metastases, represents substantial market growth.
Partnerships with pharmaceutical companies for clinical trial stratification or companion diagnostic development offer a strategic revenue and validation pathway.
Risk Factors
Key risks include the challenge of securing widespread payer reimbursement, which requires robust clinical utility evidence proving improved patient outcomes.
The technical complexity and variability of processing live tumor samples poses operational risks to assay success rates.
The company faces competition from established genomic profiling firms and must convince oncologists to adopt a new testing paradigm with a 7-10 day wait time.
Competitive Landscape
Kiyatec competes in the precision oncology space against dominant genomic profiling companies like Foundation Medicine and Guardant Health. Its direct competitors are other functional precision medicine companies using ex vivo assays, such as Inspirna (formerly Rgenix) and some academic lab-developed tests, though technological approaches differ. Kiyatec's key differentiator is its focus on 3D microtumor culture and a clinically actionable turnaround time.
